Pharmaceutical company HaiHe Biopharma has raised $146m in a funding round led by Huagai and backed by investors including OncoCapital and Yingke. The new fund will invest in companies that are developing drugs to treat diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s disease. Most of the funding will be used to develop the firm’s clinical and preclinical oncology drugs. Hai­He Bio­phar­ma was found­ed in 2011 by Jian Ding, the dean of CAS’ Col­lege of Phar­ma­cy, to pur­sue on­col­o­gy drugs. It has already won approval for more than 12 trials. HaiHe joined forces with RMX Biopharma in March 2018.
Pharmaceutical company HaiHe Biopharma has raised $146m in a funding round led by Huagai and backed by investors including OncoCapital and Yingke. The new fund will invest in companies that are developing drugs to treat diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s disease. Most of the funding will be used to develop the firm’s clinical and preclinical oncology drugs. It has already won approval for more than 12 trials. HaiHe joined forces with RMX Biopharma in March 2018.